MET and hepatocellular carcinoma: (37) reported the spectrum of genomic mutations in ctDNA from 14 HCC patients by a 68-gene NGS panel, and all patients had somatic alterations, of which the most predominant somatic mutations were in TP53 (57%), followed by CTNNB1 (29%), PTEN (7%), CDKN2A (7%), ARID1A (7%), and MET (7%).